Enoblituzumab Plus MGA012 in Squamous Cell Carcinoma of the Head and Neck

Conditions:   Head and Neck Cancer;   Squamous Cell Carcinoma of Head and Neck Interventions:   Biological: pembrolizumab;   Biological: enoblituzumab;   Biological: MGA012;   Drug: Chemotherapeutic Combinations Sponsor:   MacroGenics Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials